×
Home
Archive Submission Guidelines
News Contact
Original article
Crossmark

Viral Myocarditis-Diagnostic and Therapeutic Challenge for Physicians

By
Dejan Simonović ,
Dejan Simonović
Marina Ilić
Marina Ilić

Abstract

Myocarditis is defined as inflammation of the heart muscle according to clinical, immunohistological and pathological criteria. Myocarditis can manifest a wide spectrum of symptoms ranging from mild dyspnea or chest pain, and sometimes without a specific therapy it can lead to cardiogenic shock and death, too. According to the evidence, the incidence of myocarditis is 8-10 cases per 100.000 humans, and the prevalence of non-selected autopsies is 1-5 per 100 cases. The most common possible triggers for myocarditis are: coxsackie virus B3, parvovirus B19, adenovirus, and human herpesvirus 6. Viral myocarditis appears in three stages: acute viral infection, inflammatory cell infiltration, and myocardial remodeling. The initial patient evaluation includes a detailed history and a careful physical examination which should include an electrocardiogram, chest X-ray, blood studies, non-invasive imaging techniques. The diagnosis of myocarditis can only be obtained by investigations of endomyocardial biopsy, including: histology, immunohistology and molecular biology or virology. Therapy can be divided into supportive and specific therapy (immunosuppressive therapy, interferon, immunoglobulin, immune-adsorptive therapy, immune-modulation, vaccination).

References

1.
Mahfoud F, Gartner B, Kindermann M, Ukena C, Gadomski K, Klingel K, et al. Virus serology in patients with suspected myocarditis: utility or futility? European Heart Journal. 2011;32(7):897–903.
2.
Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. European Heart Journal. 2009;30(16):1995–2002.
3.
Schmidt‐Lucke C, Spillmann F, Bock T, Kühl U, Van Linthout S, Schultheiss H, et al. Interferon Beta Modulates Endothelial Damage in Patients with Cardiac Persistence of Human Parvovirus B19 Infection. The Journal of Infectious Diseases. 2010;201(6):936–45.
4.
Kühl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, et al. Interferon-β Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction. Circulation. 2003;107(22):2793–8.
5.
Schultheiss HP, Kuhl U, Cooper LT. The management of myocarditis. European Heart Journal. 2011;32(21):2616–25.

Citation

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.